Denali Therapeutics Inc. (DNLI)

Market Cap	2.20B
Revenue (ttm)	330.53M
Net Income (ttm)	-145.22M
Shares Out	142.54M
EPS (ttm)	-1.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,093,786
Open	15.11
Previous Close	14.96
Day's Range	14.90 - 15.49
52-Week Range	14.56 - 33.31
Beta	1.33
Analysts	Strong Buy
Price Target	45.44 (+194.49%)
Earnings Date	May 10, 2024

About DNLI

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HE...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 8, 2017
• Employees: 445
• Stock Exchange: NASDAQ
• Ticker Symbol: DNLI

Financial Performance

In 2023, DNLI's revenue was $330.53 million, an increase of 204.74% compared to the previous year's $108.46 million. Losses were -$145.22 million, -55.45% less than in 2022.

Analyst Forecast

According to 9 analysts, the average rating for DNLI stock is "Strong Buy." The 12-month stock price forecast is $45.44, which is an increase of 194.49% from the latest price.

Price Target

$45.44

(194.49% upside)

Analyst Consensus: Strong Buy